Bridges Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bridges Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-3,739	Closed	-$1.04M	–	364
2019 Q3	$1.04M	Buy	3,739 +429	+13%	+$127K	0.04%	197
2019 Q2	$1.04M	Buy	3,310 +110	+3%	+$36.6K	0.04%	192
2019 Q1	$1.31M	Hold	3,200	–	–	0.05%	170
2018 Q4	$1.2M	Buy	3,200 +1,855	+138%	+$679K	0.06%	162
2018 Q3	$543K	Buy	+1,345	New	+$512K	0.03%	196

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Bridges Investment Management's REGN Position: Q4 2019 in Review

Bridges Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2019, closing a stake of 3,739 shares — an estimated $1.04M sold.

Bridges Investment Management first reported a position in REGN in Q3 2018 and held it in 5 quarters. The position peaked at $1.31M in Q1 2019. 702 funds tracked by Wall St. Rank hold REGN as of Q4 2019.

Bridges Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Bridges Investment Management sold 3,739 Regeneron Pharmaceuticals shares in Q4 2019, an estimated $1.04M.
Bridges Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 5 quarters.
Bridges Investment Management's Regeneron Pharmaceuticals position peaked at $1.31M in Q1 2019.
702 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2019.

Based on Bridges Investment Management's 13F filing for Q4 2019, filed 18 Feb 2020.